| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Lesinurad |
| Brand | Zurampic® |
| Indication | For the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor. |
| Assessment Process | |
| Rapid review commissioned | 15/03/2017 |
| Rapid review completed | 20/03/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 29/03/2017 |
| Pre-submission consultation with Applicant | 22/05/2017 |
| Full submission received from Applicant | 07/06/2018 |
| Preliminary review sent to Applicant | 18/07/2018 |
| NCPE assessment re-commenced | 15/08/2018 |
| Factual accuracy sent to Applicant | 15/11/2018 |
| NCPE assessment re-commenced | 21/11/2018 |
| NCPE assessment completed | 06/12/2018 |
| NCPE assessment outcome | The NCPE recommends that lesinurad not be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.